Angiopoietin-1 and Angiopoietin-2 in metabolic disorders: therapeutic strategies to restore the highs and lows of angiogenesis in diabetes
- 25 June 2016
- journal article
- review article
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 39 (11) , 1235-1246
Abstract
The morbidity and mortality of diabetes mellitus are mostly attributed to cardiovascular complications. Despite tremendous advancement in glycemic control, anti-diabetic medications have failed to revert vascular impairment once triggered by the metabolic disorder. The angiogenic growth factors, Angiopoietin-1 (Ang1) and Angiopoietin-2 (Ang2), are crucial regulators of vessel formation and maintenance starting with embryonic development and continuing through life. In mature vessels, angiopoietins control vascular permeability, inflammation and remodeling. A crucial role of angiopoietins is to drive vascular inflammation from the active to the quiescent state, enabling restoration of tissue homeostasis. The mechanism is of particular importance for healing and repair after damage, two conditions typically impaired in metabolic disorders. There is an emerging body of evidences suggesting that the imbalance of Ang1 and Ang2 regulation, leading to an increased Ang2/Ang1 ratio, represents a culprit of the vascular alterations of patients with type-2 diabetes mellitus. Pharmacological modulation of Ang1 or Ang2 actions may help prevent or delay the onset of diabetic vascular complications by restoring vessel function, favoring tissue repair and maintaining endothelial quiescence. In this review, we present a summary of the role of Ang1 and Ang2, their involvement in diabetic complications, and novel therapeutic strategies targeting angiopoietins to ameliorate vascular health in metabolic disorders.Keywords
Funding Information
- Italian Ministry of Instruction, University and Research (RBFR10URHP)
This publication has 138 references indexed in Scilit:
- Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisitedActa Neuropathologica, 2012
- Overexpression of angiopoietin-2 impairs myocardial angiogenesis and exacerbates cardiac fibrosis in the diabetic db/db mouse modelAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- Angiopoietin/Tie2 pathway mediates type 2 diabetes induced vascular damage after cerebral strokeNeurobiology of Disease, 2011
- A Potential Role for Angiopoietin 2 in the Regulation of the Blood–Retinal Barrier in Diabetic RetinopathyInvestigative Ophthalmology & Visual Science, 2011
- Clinical and Genetic Correlates of Circulating Angiopoietin-2 and Soluble Tie-2 in the CommunityCirculation: Cardiovascular Genetics, 2010
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 2010
- Additive effect of AAV-mediated angiopoietin-1 and VEGF expression on the therapy of infarcted heartInternational Journal of Cardiology, 2009
- Hyperoxia causes angiopoietin 2–mediated acute lung injury and necrotic cell deathNature Medicine, 2006
- Angiogenesis in life, disease and medicineNature, 2005
- Angiopoietin-1 Inhibits Endothelial Cell Apoptosis via the Akt/Survivin PathwayJournal of Biological Chemistry, 2000